DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
Chi G, Yee MK, Amin AN. , et al.
Extended-duration betrixaban reduces the risk of rehospitalization associated with venous thromboembolism among acutely ill hospitalized medical patients: findings from the APEX trial (Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban Trial).
Circulation 2018;
137 (01) 91-94
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.